Leadership
Leadership Team Comprises Expertise Necessary to Develop Products & Company

Christopher Marshall PhD, President & CEO
Founded three biotechs, is an inventor and former strategy consultant.


Dirk Pleimes, MD, CMO
Founded four biotechs and worked in clinical development in large pharma. Expert in respiratory-inflammatory disease.


Mark Yondola, PhD, CSO
Established Calder’s bioprocess technology. Expert in vaccine design, protein chemistry and virology.


Susan Stella, MBA, Interim COO
Expert strategist with emerging tech & life science companies as well as investors.

Scientific Advisory Board

Barry Buckland, PhD
Merck Vaccines, VP Manufacturing for 16 years. Manufactured a large number of approved vaccine products.


Florian Schödel, MD
Merck Vaccines, VP Clinical Research for 8 years. Directed clinical studies for licensure of multiple approved vaccines.


Jason S. McLellan, PhD
Univ. of Texas. Pre-eminent in vaccine design. Most Covid-19 vaccines programs based on Jason’s 2P-design.


Alexander Hoffmann, PhD
UCLA. Pre-eminent in the field of innate immunity (adjuvants); Director, Instit. for Quant. & Computational Biosciences.

Key Personnel

Devarshi Brahmbhatt, MS
Expert in downstream process development.


Sonal Gidwani, MS
Expert in crosslinking chemistry and controls; analytical development.

Collaborating Scientists

Barney Graham, MD, PhD
Deputy Director, Vaccine Research Center, NIAID/NIH
Collaborator in RSV immunogen design.


James E. Crowe, Jr., MD
Director, Vanderbilt Vaccine Center, VUMC; IDBiologics
Collaborator in universal flu immunogen design.


Kerry Empey, PharmD, PhD
Assoc. Professor, Dept. Pharmacy and Therapeutics
Collaborator in adjuvant selection for maternal RSV vaccine.


Bonnie Blomberg, PhD
Prof. of Microbiology and Immunology, Univ. of Miami
Collaborator in adjuvant selection for RSV vaccine for the elderly.


Daniela Frasca, PhD
Res. Asst. Prof of Microbiol. & Immunol., Univ. of Miami
Collaborator in adjuvant selection for RSV vaccine for the elderly

Experts-In-Residence

Claudio Bertuccioli, PhD
Advising on financing strategies. Biotech VC for 15 years.


Heidi Agostini, PhD
Consulting on govt. funding strategies. Obtained & executed $200M-$7B BARDA/DoD/NIH contracts.


James E. Hough, JD
Consulting on communications and strategy; partner at Morrison & Foerster LLP for 25+ years
